

**Amendments to the Claims:**

1. (Currently amended) A hybrid bacterial toxin subunit comprising an **A1-part and an A2-part fused together, wherein the A1-part is the** A1-part of Shiga-toxin or Shiga-like toxin **fused to an and the A2-part is the** A2-part of **Escherichia coli Escherichia coli** heat-labile enterotoxin.
2. (Currently amended) The hybrid bacterial toxin subunit according to claim 1, wherein the A1-part is the A1-part of Stx2e.
3. (Currently amended) A hybrid bipartite bacterial toxin comprising five B-subunits of **Escherichia coli Escherichia coli** heat-labile enterotoxin and the hybrid bacterial toxin subunit according to claim 1, **wherein the A1-part is optionally the A1-part of Stx2e.**

Claims 4-9 (Cancelled).

10. (Currently amended) A vaccine comprising the hybrid bacterial toxin subunit according to claim 1 and a pharmaceutically acceptable carrier, **wherein the A1-part is optionally the A1-part of Stx2e.**

Claims 11-13 (Cancelled)

14. (currently amended) The vaccine according to claim 10, wherein said vaccine further comprises an additional antigen **derived from a virus or of a** micro-organism pathogenic to **humans or animals, an antibody against said antigen or genetic information encoding said antigen.**

15. (currently amended) The vaccine according to claim 14, wherein said vaccine comprises ~~a virus or micro-organism selected from the group consisting of Pseudorabies virus, Porcine influenza virus, Porcine parvo virus, Transmissible gastro-enteritis virus, Rotavirus, Brachyspira hyodysenteriae, Escherichia coli, Erysipelothrix rhusiopathiae, Bordetella bronchiseptica, Brachyspira hyodysenteriae, Shigella sp., Salmonella choleraesuis, Salmonella typhimurium, Salmonella enteritidis, Haemophilus parasuis, Pasteurella multocida, Streptococcus suis, Mycoplasma hyopneumoniae, Actinobacillus pleuropneumoniae, Staphylococcus hyicus and Clostridium perfringens.~~

16. (currently amended) A method of combatting ~~Shigella or Escherichia coli~~ infection comprising administering an immunogenically effective amount of

(i) the hybrid bacterial toxin subunit according to claim 1, or

(ii) a hybrid bipartite bacterial toxin comprising five B-subunits of Escherichia coli heat-labile enterotoxin and the hybrid bacterial toxin subunit according to claim 1, ~~whererein the A1-part is optionally the A1-part of Stx2e.~~

17. (currently amended) A method for the preparation of a vaccine, said method comprising the admixing of

the hybrid bacterial toxin subunit according to claim 1 and a pharmaceutically acceptable carrier, ~~whererein the A1-part is optionally the A1-part of Stx2e.~~

Claims 18-21 (Cancelled).

USSN 10/565,183

Attorney Docket: I-2003.006 US

Amendment in response to the OA of 9/3/09

22. (New) The hybrid bipartite bacterial toxin of claim 3, wherein the A1-part of the hybrid bacterial toxin subunit is the A1-part of Stx2e.

23. (New) The vaccine of claim 10, wherein the A1-part of the hybrid bacterial toxin subunit is the A1-part of Stx2e.

24. (New) The method of claim 16, wherein the A1-part of the hybrid bacterial toxin subunit is the A1-part of Stx2e.

25. (New) The method of claim 17, wherein the A1-part of the hybrid bacterial toxin subunit is the A1-part of Stx2e.